Literature DB >> 30190808

Subcutaneous metastases from melanoma: a discussion of clinical experience.

Piotr Rutkowski1, Marcin Zdzienicki1, Katarzyna Kozak1.   

Abstract

The majority of locoregional relapses of cutaneous melanoma occur as subcutaneous local recurrences/in-transit metastases; subcutaneous metastases (SMs) are also common in distant metastases. SM therapy is challenging and depends on the number, site, depth, size, clinical behavior and presence of other metastases. Isolated, resectable SMs should be treated surgically. In multiple/unresectable lesions, several local modalities are used: carbon dioxide laser ablation, radiotherapy, cryotherapy, intralesional injections and electrochemotherapy. Hyperthermic isolated limb perfusion is the preferred method of treating multiple, bulky in-transit metastases in extremities, allowing for high response rates and long-lasting remission. Electrochemotherapy is a simple method for the fast ablation of SMs that are not feasible for hyperthermic isolated limb perfusion. Recent advances in systemic therapy of melanoma, including immunotherapy (anti-CTLA4/anti-PD-1) and targeted therapy (BRAF/MEK inhibitors), have significantly impacted on SM treatment. We present our own SM cases treated with different modalities. The future of SM therapy will rely on a combination of different local, locoregional and systemic modalities, and we can expect major improvements in long-term outcomes.

Entities:  

Keywords:  electrochemotherapy; in-transit metastases; isolated limb perfusion; local recurrence; melanoma

Year:  2014        PMID: 30190808      PMCID: PMC6094878          DOI: 10.2217/mmt.14.1

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


  47 in total

1.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

Authors:  D Liénard; A M Eggermont; H S Koops; B Kroon; G Towse; S Hiemstra; P Schmitz; J Clarke; G Steinmann; F Rosenkaimer; F J Lejeune
Journal:  Melanoma Res       Date:  1999-10       Impact factor: 3.599

2.  Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser.

Authors:  N C Zeitouni; K Dawson; R T Cheney
Journal:  Br J Dermatol       Date:  2005-02       Impact factor: 9.302

3.  Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy).

Authors:  Christopher M Byrne; John F Thompson; Heather Johnston; Peter Hersey; Michael J Quinn; T Michael Hughes; William H McCarthy
Journal:  Melanoma Res       Date:  2005-02       Impact factor: 3.599

4.  Chemoablation of metastatic melanoma using intralesional Rose Bengal.

Authors:  John F Thompson; Peter Hersey; Eric Wachter
Journal:  Melanoma Res       Date:  2008-12       Impact factor: 3.599

5.  Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan.

Authors:  F J Lejeune; T Deloof; P Ewalenko; J Fruhling; M Jabri; M Mathieu; J M Nogaret; A Verhest
Journal:  Recent Results Cancer Res       Date:  1983

6.  Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases.

Authors:  Carlo Riccardo Rossi; Sandro Pasquali; Simone Mocellin; Antonella Vecchiato; Luca Giovanni Campana; Pierluigi Pilati; Antonio Zanon; Donato Nitti
Journal:  Ann Surg Oncol       Date:  2010-04-29       Impact factor: 5.344

7.  Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.

Authors:  Slawomir Majewski; Maria Marczak; Beata Mlynarczyk; Bernd Benninghoff; Stefania Jablonska
Journal:  Int J Dermatol       Date:  2005-01       Impact factor: 2.736

8.  Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases.

Authors:  G Sersa; B Stabuc; M Cemazar; D Miklavcic; Z Rudolf
Journal:  Melanoma Res       Date:  2000-08       Impact factor: 3.599

Review 9.  Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis.

Authors:  B Mali; T Jarm; M Snoj; G Sersa; D Miklavcic
Journal:  Eur J Surg Oncol       Date:  2012-09-11       Impact factor: 4.424

10.  Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases.

Authors:  P Quaglino; C Mortera; S Osella-Abate; M Barberis; M Illengo; M Rissone; P Savoia; M G Bernengo
Journal:  Ann Surg Oncol       Date:  2008-05-23       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.